The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.
Sign Up to like & getrecommendations! Published in 2025 at "Blood cancer journal"
DOI: 10.1038/s41408-025-01414-6
Abstract: Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), is effective in relapsed or refractory multiple myeloma (RRMM), but its impact on patients with soft tissue plasmacytomas is unclear. We studied 385 RRMM patients treated… read more here.
Keywords: multiple myeloma; plasmacytomas; true emd; treated teclistamab ... See more keywords